[ad_1]
Glancy Prongay & Murray LLP (“GPM”), announcing that it has filed an amended class action complaint in the U.S. District Court for the Northern District of Illinois, titled Colwell v. Exicure, Inc. et al., (Case No. 21-cv-6637), expanding category definition to cover individuals and entities that purchase or otherwise acquire Exicure, Inc. (“Exicure” or the “Company”) (NASDAQ: XCUR) between securities January 7, 2021 and December 10, 2021, inclusive (“during class”). Plaintiff’s claim is under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
Exicure investors have until February 11, 2022 File a lead plaintiff motion.
If you incur losses in your Exicure investments, or would like to inquire about possible claims under the federal securities laws to recover your losses, you may submit your contact information at www.glancylaw.com/cases/exicure-inc/. You can also contact Charles H. Linehan of GPM at 310-201-9150, toll-free at 888-773-9224, or email at shareholders@glancylaw.com or visit our website www.glancylaw.com Learn more about your rights.
On November 15, 2021, after the market closed, Exicure filed a Form 12b-25 with the SEC, stating that it was unable to file a timely report for the quarter ended September 30, 2021. It explained that the company is investigating “a claim” by a former senior researcher at the company regarding allegations of misconduct by the researcher in relation to the company’s XCUR-FXN preclinical program for the treatment of Friedreich’s ataxia. ”
Affected by this news, on November 16, 2021, the company’s stock price fell by $0.293, or 27.4%, to close at $0.777 per share, with unusually large trading volume.
Then, on November 19, 2021,…
The full story is available on Benzinga.com
[ad_2]
Source link
